NCT07095062 Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Connectome. Status RECRUITING Phase NA
NCT04102501 A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia Status COMPLETED Phase PHASE3
NCT02840669 A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study) Status COMPLETED Phase NA
NCT02797080 Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia Status COMPLETED Phase PHASE3
NCT02593773 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study Status COMPLETED Phase PHASE3
NCT02445794 A First in Human Study of RT001 in Patients With Friedreich's Ataxia Status COMPLETED Phase PHASE1/PHASE2
NCT02415127 Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Status COMPLETED Phase PHASE3
NCT02316314 Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) Status RECRUITING Phase N/A
NCT02179333 Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND) Status COMPLETED Phase N/A
NCT02069509 Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) Status COMPLETED Phase N/A
NCT01921868 An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia Status UNKNOWN Phase NA
NCT01898884 Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia Status COMPLETED Phase PHASE1
NCT01728064 Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia Status COMPLETED Phase PHASE2
NCT01303406 Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI) Status COMPLETED Phase PHASE3
NCT01035671 Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia Status COMPLETED Phase PHASE2
NCT01016366 Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia Status COMPLETED Phase PHASE2